Details of Drug-Drug Interaction
| Drug General Information (ID: DDI68JDA9X) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Orlistat | Drug Info | Glycerol phenylbutyrate | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiobesity Agents | Urea Cycle Disorder Agents | |||||||
| Structure | |||||||||
| Mechanism of Orlistat-Glycerol phenylbutyrate Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Altered absorption (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Orlistat | Glycerol phenylbutyrate | |||||||
| Mechanism | Orlistat | Absorption possibly altered by orlistat | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacokinetic | ||||||||
| Factor Description | Alters the absorption of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution and close monitoring of ammonia levels is recommended if glycerol phenylbutyrate is to be administered with a gastrointestinal lipase inhibitor such as orlistat. The dose of glycerol phenylbutyrate should be adjusted as necessary per local guidelines. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||||||||||||||||
| 2 | Product Information. Ravicti (glycerol phenylbutyrate). Hyperion Therapeutics Inc, South San Francisco, CA. | ||||||||||||||||||